Ipamorelin — Research Profile
Ipamorelin is a pentapeptide that acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a). Research has examined its action on pulsatile growth hormone release with compar...
Overview
Ipamorelin is a pentapeptide that acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a). Research has examined its action on pulsatile growth hormone release with comparatively limited off-target activity on prolactin and cortisol axes.
History
Ipamorelin was developed in the 1990s as part of the GHSR ligand research program, alongside other GHRPs (growth hormone–releasing peptides). Its selectivity profile made it a frequent comparator in receptor-selectivity studies.
Ipamorelin Structure
- CAS #: 170851-70-4
- Molecular Formula: C₃₈H₄₉N₉O₅
- Molecular Weight: 711.85 g/mol
- PubChem ID: 11375645
Research Findings
Ipamorelin has been characterized in receptor-binding assays and animal models exploring GH release, IGF-1 dynamics, and selectivity versus prolactin/cortisol axes.
Key Areas of Research
- Somatotropic: GHSR-1a agonism, GH pulsatility
- Selectivity: limited prolactin/cortisol activity
- Endocrine: IGF-1 downstream dynamics
Ipamorelin is among the more receptor-selective GHRP research peptides, making it useful in studies designed to isolate GH-axis effects.
References
- [1]Raun K. et al. Ipamorelin, the first selective growth hormone secretagogue. (1998).
- [2]Sun D. et al. GHSR ligands in metabolic and growth hormone research. (2018).
All references link to the corresponding PubMed record. Citations maintained for transparency — Viora articles are sourced from the published research literature.